をいずれか含む
  • 全て含む
  • いずれか含む
189337385

Indian vaccine giant Serum plans African plant in global expansion


このコンテンツは出版・報道コンテンツをご利用いただける
アカウントでログイン後に閲覧できます。
ご不明点はアフロカスタマーセンターまでお問い合わせ下さい。

ライトボックスに追加 カンプデータをダウンロードする 印刷

作品情報

作品番号
189337385
タイトル
Indian vaccine giant Serum plans African plant in global expansion
クレジット表記
動画:ロイター/アフロ
日付
2022年5月23日
撮影国
スイス
コンテンツカテゴリー
ヨーロッパ, ニュース
ライセンスタイプ
RM(ライツマネージド)
モデルリリース
なし 
プロパティリリース
なし 
コーデック
H264
フレームレート
25.00 fps
長さ
202.16 秒
もっと見る

ストーリー

The Serum Institute of India (SII), the world's biggest vaccine maker, is considering setting up its first manufacturing plant in Africa as it looks to expand globally after its success in selling COVID-19 shots, its CEO told Reuters on Monday (May 23).
Africa was the only continent that did not have its own manufacturing capacity for COVID shots during the worst phases of the pandemic in the last two years, leaving it at the mercy of suppliers from overseas, including the SII.
"It's never been a better time to be a vaccine manufacturer. I'm looking at expanding our manufacturing across the globe," SII Chief Executive Adar Poonawalla said during an interview at the World Economic Forum in Davos.
"There are some great countries out there: South Africa, Rwanda, you know, to name a few that we're looking at."
Poonawalla said he was meeting some African officials in Davos to discuss his plans.
Asked about possible investments, he said such projects typically required at least around $300 million.
He did not say what products an African plant might make.
Apart from COVID shots, the SII's Indian plants make vaccines for diphtheria, BCG, measles, rubella and other conditions.
Asked about concerns over the rise of monkeypox cases, Poonawalla said he believed the disease was not so infectious.
"We'll wait and see even if we want to make a vaccine for it," he said.
Monkeypox is usually mild and is endemic in parts of west and central Africa.
The World Health Organization has said it expects to identify more cases as it expands surveillance in countries where the disease is not typically found.
On COVID, the SII has sold more than 1.5 billion doses in India of the AstraZeneca AZN.L shot it makes and brands Covishield, and exported millions more.
But as demand has now waned, the company is putting its Indian Covishield facilities on standby and will "not produce anything there," Poonawalla said, while adding it could resume output if needed.
The SII has also pulled the plug on a plan to produce and sell about 300 million doses of Russia's Sputnik Light COVID vaccine. However, it is still making millions of doses of a version of the Novavax NVAX.O COVID shot for India and other countries, Poonawalla said.
He estimated privately held SII was now valued at roughly $20 billion, but said there was no immediate plan to go public.
(Production: Antonio Denti, Tara Oakes)
( Original Title: Indian vaccine giant Serum plans African plant in global expansion )
( Caption: 0086BU-DAVOS-MEETING_SII_INDIA_O_ )
もっと見る

タイムライン

DAVOS, SWITZERLAND (MAY 23, 2022) (REUTERS)
CEO OF SERUM INSTITUTE OF INDIA, ADAR POONAWALLA, ARRIVING FOR INTERVIEW
POONAWALLA BEING INTERVIEWED
(SOUNDBITE) (English) CEO OF SERUM INSTITUTE OF INDIA, ADAR POONAWALLA, SAYING:
"You know, it's never been a better time to be a vaccine manufacturer. We've got so many partnerships coming our way, building on, you know, all the non-COVID future pipeline that we've been working on. We want to accelerate that. So and also broaden our manufacturing footprint globally out of India as well."
POONAWALLA BEING INTERVIEWED
(SOUNDBITE) (English) CEO OF SERUM INSTITUTE OF INDIA, ADAR POONAWALLA, SAYING:
"We've already got a facility in the Netherlands, so we've got capacity in Europe. We've built a 150 million dose capacity in the UK for drug substance and finished goods. So we've already got some capacity outside of India and we'll probably look at something on the African continent because, you know, in this pandemic, one thing was very clear. Most regions or groups of countries that did not have access to vaccines suffered a little bit. They had to wait a little bit longer. And they all want investment in those nations. So we'll have to pick the right environment. You know, don't forget, some of these countries don't even have a regulatory framework which would allow the testing and release of these products. So, you know, as we see that new ecosystem evolves, we're looking very....Looking forward to, you know, very much investing in other parts of the world that we've not looked at before."
POONAWALLA BEING INTERVIEWED
(SOUNDBITE) (English) CEO OF SERUM INSTITUTE OF INDIA, ADAR POONAWALLA, SAYING:
"Well, we're looking at different countries at the moment have been meeting some leader.? It wouldn't be right to right now to mention what that would be. But, you know, there's some great countries out there, South Africa, Rwanda, you know, to name a few. But we're looking at, let's see what happens."
POONAWALLA BEING INTERVIEWED
(SOUNDBITE) (English) CEO OF SERUM INSTITUTE OF INDIA, ADAR POONAWALLA, ON MONKEYPOX,SAYING:
"No no, it's very small and isolated at the moment. It is not as infectious and airborne like you have flu or coronaviruses. Thank God for that, because it's a terrible disease. So it's not so contagious. At the moment we'll wait and watch. There is a smallpox vaccine, as you may have heard, which can treat it. I don't know the data on it, so I don't want to comment on it, it's very early days. We'll wait and see if we even want to get into making a vaccine for it. But I hope and I think I believe it will die down, but I don't want to make any forward looking statements."
POONAWALLA BEING INTERVIEWED
もっと見る

サイズ

フレームサイズ
SD 864 × 486
形式
MP4

料金

プライスゾーン
Standard(料金案内)

ご利用上の注意

  • 被写体やご利用方法によっては、被写体管理者から事前に使用許可を得る必要がある場合があります。
  • 本作品を「TV番組・出版・報道・教育目的」以外でご使用の際は、事前申請が必要です。
    営利目的での使用をご検討の場合は、媒体に関わらずアフロカスタマーセンターまでお問合せください。

このコンテンツの
ご注文は電話・メールにて
承っております。

このコンテンツは、「使用に際して特別な注意事項がある」「別途著作権等の処理が必要」「準備に時間を要する」などの理由により、オンライン注文に対応していません。ご利用を希望される方はカスタマーセンターまでお問合せください。
アフロカスタマーセンター
営業時間<年中無休> 9:30~22:00
広告・販促・ウェブ
0120-565-410
sagasu@aflo.com
報道・出版・教育
0120-656-410
houdou@aflo.com
TV番組
0120-707-410
tv@aflo.com

キーワード

キーワードは画像や動画を検索するための便宜的なものであり、必ずしも画像や動画の内容を表すものではありません。
また、特定の思想やイメージを表すキーワードが付与されていても、そのキーワードと画像や動画の内容とを関連づける意図はないことにご留意ください。